Palisade Bio (PALI) Common Equity (2010 - 2026)

Palisade Bio (PALI) has 17 years of Common Equity data on file, last reported at $127.4 million in Q1 2026.

• Common Equity for Q1 2026 came in at $127.4 million, up 2289.08% year-over-year; the trailing twelve-month figure through Mar 2026 was $127.4 million (up 2289.08% YoY), and the FY2025 annual result was $129.4 million, up 1626.91% from the prior year.
• Common Equity declined to $127.4 million in Q1 2026 per PALI's latest filing, from $129.4 million in the prior quarter.
• Over five years, Common Equity peaked at $129.4 million in Q4 2025 and troughed at $2.6 million in Q2 2025.
• A 5-year average of $23.0 million and a median of $10.1 million in 2024 frame the typical range for Common Equity.
• The sharpest annual moves came in 2025 and 2026: Common Equity slumped 73.67% in 2025, then jumped 2289.08% in 2026.
• A 5-year view of Common Equity shows it stood at $12.5 million in 2022, then dropped by 9.34% to $11.3 million in 2023, then plunged by 33.78% to $7.5 million in 2024, then surged by 1626.91% to $129.4 million in 2025, then retreated by 1.56% to $127.4 million in 2026.
• Business Quant data shows PALI's Common Equity at $127.4 million in Q1 2026, $129.4 million in Q4 2025, and $3.2 million in Q3 2025.